Principal Securities, Inc. Supernus Pharmaceuticals, Inc. Transaction History
Principal Securities, Inc.
- $5.32 Trillion
- Q2 2025
A detailed history of Principal Securities, Inc. transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Principal Securities, Inc. holds 253 shares of SUPN stock, worth $12,397. This represents 0.0% of its overall portfolio holdings.
Number of Shares
253
Previous 230
10.0%
Holding current value
$12,397
Previous $8.32 Million
4.11%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding SUPN
# of Institutions
315Shares Held
61.7MCall Options Held
18.4KPut Options Held
0-
Black Rock Inc. New York, NY10.4MShares$509 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.21MShares$304 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY4.81MShares$236 Million2.66% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.02MShares$148 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.76MShares$135 Million0.11% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $2.62B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...